How many Iberdomide clinical trials are there?

35 Iberdomide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 18 are actively recruiting participants. 2 are marked completed.

Are Iberdomide clinical trials recruiting in 2026?

Yes — 18 Iberdomide trials are actively recruiting in 2026, with 165 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Iberdomide being studied for?

Iberdomide is being studied for Multiple Myeloma, Refractory Multiple Myeloma, Recurrent Multiple Myeloma, Relapsed Multiple Myeloma, Non-Hodgkin Lymphoma and 12 more. The trials are grouped by indication on this page.

What phase is Iberdomide in?

Iberdomide clinical trials span 4 Phase 3, 12 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Iberdomide clinical trials?

The lead sponsor across the most Iberdomide trials is Bristol-Myers Squibb, with 26 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Iberdomide Clinical Trials (2026): 35 Studies for Multiple Myeloma & Refractory Multiple Myeloma

Creator: Hipa.ai Research
Published: 2026-04-27T18:23:07.842Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 12, 2026.

35 Iberdomide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 14 indications (including Multiple Myeloma & Refractory Multiple Myeloma) and 5,185 total planned enrollment. 4 Phase 3 Iberdomide trials and 12 Phase 2 are listed. 20 Iberdomide clinical trials are actively recruiting at 165 U.S. sites across 33 states. Most recent activity: NCT06896916 (Mar 2036).

Where to Participate: All Iberdomide Trial Sites in the U.S. (165 sites across 33 states)

Every actively recruiting Iberdomidetrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AL	University of Alabama at Birmingham	Birmingham35294-3300	NCT06121843	Map
AZ	Mayo Clinic Hospital in Arizona	Phoenix85054	NCT06465316	Map
AZ	Mayo Clinic in Arizona - Phoenix	Phoenix85054	NCT06121843	Map
CA	Beverly Hills Cancer Center /ID# 266921	Beverly Hills90211	NCT06896916	Map
CA	City of Hope Comprehensive Cancer Center	Duarte91010	NCT06121843	Map
CA	UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program	San Francisco94143	NCT05169515	Map
CA	University of Calfornia, San Francisco	San Francisco94143	NCT06348108	Map
CO	Rocky Mountain Cancer Centers	Aurora80012-5405	NCT05827016	Map
CO	University of Colorado	Aurora80045	NCT05169515	Map
CO	Colorado Blood Cancer Institute /ID# 273751	Denver80218	NCT06896916	Map
CT	Smilow Cancer Hospital-Derby Care Center	Derby06418	NCT06465316	Map
CT	Smilow Cancer Hospital Care Center - Guilford	Guilford06437	NCT06465316	Map
CT	Yale University	New Haven06520	NCT06465316	Map
CT	Yale-New Haven Hospital North Haven Medical Center	North Haven06473	NCT06465316	Map
DC	Lombardi Comprehensive Cancer Center	Washington D.C.20007	NCT05199311	Map
FL	Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center	Coral Gables33146	NCT06215118	Map
FL	University of Miami Hospital and Clinics Deerfield Beach	Deerfield Beach33442	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center- Doral	Doral33166	NCT06215118	Map
FL	Mayo Clinic Florida	Jacksonville32224	NCT05827016	Map
FL	Mayo Clinic in Florida	Jacksonville32224	NCT06121843	Map
FL	Mayo Clinic in Florida	Jacksonville32224-9980	NCT06465316	Map
FL	Sylvester Comprehensive Cancer Center	Miami33136	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center Kendall	Miami33176	NCT06215118	Map
FL	University of Miami	Miami33136	NCT05896228	Map
FL	University of Miami Hospital and Clinics	Miami33136	NCT06215118	Map
FL	Sylvester Comprehensive Cancer Center Plantation	Plantation33324	NCT06215118	Map
FL	H. Lee Moffitt Cancer Center & Research Institute	Tampa33612-9416	NCT05827016	Map
FL	Moffitt Cancer Center	Tampa33612	NCT05169515	Map
FL	Tampa General Hospital	Tampa33606	NCT05827016	Map
FL	Cleveland Clinic	Weston33331-3609	NCT05827016	Map
GA	University Cancer Blood Ctr	Athens30607-1465	NCT05827016	Map
GA	Emory University Hospital	Atlanta30322	NCT06215118	Map
GA	Emory University Hospital Midtown	Atlanta30308	NCT06215118	Map
GA	Emory University Hospital/Winship Cancer Institute	Atlanta30322	NCT04776395	Map
GA	Northside Hospital	Atlanta30342	NCT06121843	Map
GA	The Winship Cancer Institute of Emory University	Atlanta30322-1013	NCT05827016	Map
GA	Winship Cancer Institute	Atlanta30322	NCT06215118	Map
GA	Augusta University - Georgia Cancer Center	Augusta30912	NCT05827016	Map
IL	The University of Chicago	Chicago60637	NCT05169515	Map
IL	The University of Chicago Medical Center - Duchossois Center for Advanced Medicine	Chicago60637-1426	NCT05827016	Map
IN	Indiana CTSI Clinical Research Center (ICRC)	Indianapolis46202	NCT06215118	Map
IN	Indiana University Health University Hospital	Indianapolis46202	NCT06215118	Map
IN	Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC)	Indianapolis46202	NCT06215118	Map
IA	Mary Greeley Medical Center	Ames50010	NCT06232044	Map
IA	McFarland Clinic - Ames	Ames50010	NCT06232044	Map
IA	McFarland Clinic - Trinity Cancer Center	Fort Dodge50501	NCT06232044	Map
IA	McFarland Clinic - Marshalltown	Marshalltown50158	NCT06232044	Map
KS	University of Kansas Cancer Center	Kansas City66160	NCT06465316	Map
KS	University of Kansas Cancer Center-Overland Park	Overland Park66210	NCT06465316	Map
KS	University of Kansas Cancer Center - The Richard and Annette Bloch Cancer Care Pavilion	Westwood66205-2003	NCT05827016	Map
KS	University of Kansas Hospital-Westwood Cancer Center	Westwood66205	NCT06465316	Map
MD	University of Maryland	Baltimore21201	NCT06215118	Map
MD	Maryland Oncology Hematology, PA- Clinton	Clinton20735-4230	NCT05827016	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06121843	Map
MA	Beth Israel Deaconess Medical Center	Boston02215	NCT06518551	Map
MA	Brigham and Women's Hospital	Boston02115	NCT06215118	Map
MA	Dana Farber Cancer Institute	Boston02215	NCT06518551	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06121843	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06215118	Map
MA	Dana-Farber Cancer Institute	Boston02215	NCT06232044	Map
MA	Tufts Medical Center	Boston02111	NCT06232044	Map
MA	Dana-Farber Cancer Institute - Chestnut Hill	Newton02459	NCT06215118	Map
MA	UMass Memorial Medical Center	Worcester01655	NCT05827016	Map
MA	University of Massachusetts Chan Medical School	Worcester01655	NCT06215118	Map
MI	University of Michigan - Rogel Cancer Center	Ann Arbor48109-5000	NCT05827016	Map
MI	Henry Ford Health System - The Henry Ford Cancer Institute (HFCI) - Detroit	Detroit48202-2610	NCT05827016	Map
MI	Karmanos Cancer Institute	Detroit48201	NCT06107738	Map
MI	Cancer & Hematology Centers of Western Michigan (CHCWM)	Grand Rapids49503	NCT05827016	Map
MI	KCI at McLaren Greater Lansing	Lansing48910	NCT06107738	Map
MN	Mayo Clinic Cancer Center (MCCC) - Rochester	Rochester55905	NCT05827016	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06465316	Map
MN	Mayo Clinic in Rochester	Rochester55905	NCT06785415	Map
MN	Mayo Clinic in Rochester, Minnesota	Rochester55905	NCT06121843	Map
MN	Coborn Cancer Center at Saint Cloud Hospital	Saint Cloud56303	NCT06232044	Map
MS	Hattiesburg Clinic - Hematology & Oncology	Hattiesburg39401	NCT05827016	Map
MO	Washington University /ID# 266972	St Louis63110	NCT06896916	Map
NE	Methodist Hospital	Omaha68114	NCT06215118	Map
NE	Oncology Hematology West P.C. dba Nebraska Cancer - Methodist	Omaha68114	NCT06215118	Map
NE	Oncology Hematology West P.C. dba Nebraska Cancer Specialists	Omaha68130	NCT06215118	Map
NE	University Of Nebraska Medical Center	Omaha68198	NCT06121843	Map
NH	Dartmouth Hitchcock Medical Center	Lebanon03756	NCT06215118	Map
NJ	MSK Basking Ridge	Basking Ridge07920	NCT06215118	Map
NJ	John Theurer Cancer Center	Hackensack07601	NCT05199311	Map
NJ	John Theurer Cancer Center at Hackensack University Medical Center	Hackensack07601	NCT06121843	Map
NJ	Memorial Sloan Kettering Monmouth	Middletown07748	NCT06232044	Map
NJ	MSK Monmouth	Middletown07748	NCT06215118	Map
NJ	Memorial Sloan Kettering Bergen	Montvale07645	NCT06232044	Map
NJ	MSK Bergen	Montvale07645	NCT06215118	Map
NJ	Morristown Medical Center	Morristown07960	NCT05827016	Map
NJ	Rutgers Cancer Institute of New Jersey /ID# 266833	New Brunswick08901	NCT06896916	Map
NY	Roswell Park Cancer Institute	Buffalo14263	NCT06121843	Map
NY	Memorial Sloan Kettering Commack	Commack11725	NCT06232044	Map
NY	MSK Commack	Commack11725	NCT06215118	Map
NY	Memorial Sloan Kettering Westchester	Harrison10604	NCT06232044	Map
NY	MSK Westchester	Harrison10604	NCT06215118	Map
NY	Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy	Long Island City11101	NCT06215118	Map
NY	Perlmutter Cancer Center at NYU Langone Hematology Oncology Associates-Mineola	Mineola11501	NCT05827016	Map
NY	Columbia University Medical Center - Herbert Irving Pavilion Location	New York10032-3729	NCT05827016	Map
NY	Laura and Isaac Perlmutter Cancer Center	New York10016	NCT06121843	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06121843	Map
NY	Memorial Sloan Kettering Cancer Center	New York10065	NCT06232044	Map
NY	Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York10021	NCT06215118	Map
NY	Memorial Sloan Kettering Cancer Center - Main Campus	New York10065	NCT06215118	Map
NY	Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282	New York10065	NCT06896916	Map
NY	NYU Langone Health	New York10016-6402	NCT05827016	Map
NY	MSK Nassau	Uniondale11553	NCT06215118	Map
NY	Clinical Research Alliance	Westbury11590	NCT05827016	Map
NC	Levine Cancer Institute	Charlotte28204	NCT05827016	Map
NC	Levine Cancer Institute	Charlotte28204	NCT05169515	Map
NC	Novant Health Cancer Institute - Elizabeth	Charlotte28803-2493	NCT05827016	Map
NC	Duke University Hospital	Durham27705-3976	NCT05827016	Map
NC	University Of North Carolina Health Care - Hillsborough Campus /ID# 278230	Hillsborough27278	NCT06896916	Map
NC	Novant Health Cancer Institute Hematology - Forsyth	Winston-Salem27103	NCT05827016	Map
NC	Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center	Winston-Salem27157	NCT05827016	Map
OH	OhioHealth O'Bleness Hospital	Athens45701	NCT06232044	Map
OH	Oncology Hematology Care, Inc. - Cincinnati - Galbraith Rd	Cincinnati45236-2725	NCT05827016	Map
OH	Cleveland Clinic	Cleveland44195	NCT05827016	Map
OH	Cleveland Clinic - Fairview Hospital - Cancer Center (Moll Cancer Center)	Cleveland44111	NCT05827016	Map
OH	Columbus Oncology and Hematology Associates Inc	Columbus43214	NCT06232044	Map
OH	Doctors Hospital	Columbus43228	NCT06232044	Map
OH	Grant Medical Center	Columbus43215	NCT06232044	Map
OH	Ohio State University Comprehensive Cancer Center	Columbus43210	NCT06465316	Map
OH	Riverside Methodist Hospital	Columbus43214	NCT06232044	Map
OH	Delaware Health Center-Grady Cancer Center	Delaware43015	NCT06232044	Map
OH	Grady Memorial Hospital	Delaware43015	NCT06232044	Map
OH	Columbus Oncology and Hematology Associates	Dublin43016	NCT06232044	Map
OH	Dublin Methodist Hospital	Dublin43016	NCT06232044	Map
OH	Midwest Oncology Associates - Kansas City	Kansas64132	NCT05827016	Map
OH	OhioHealth Mansfield Hospital	Mansfield44903	NCT06232044	Map
OH	OhioHealth Marion General Hospital	Marion43302	NCT06232044	Map
OH	Cleveland Clinic - Hillcrest Hospital - Hillcrest Cancer Center	Mayfield Heights44124	NCT05827016	Map
OH	OhioHealth Pickerington Methodist Hospital	Pickerington43147	NCT06232044	Map
OH	OhioHealth Westerville Medical Campus/Westerville Cancer Center	Westerville43082	NCT06232044	Map
OH	Wooster Milltown Specialty and Surgery Center	Wooster44691	NCT05827016	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06232044	Map
OK	University of Oklahoma Health Sciences Center	Oklahoma City73104	NCT06465316	Map
OR	Willamette Valley Cancer Institute	Eugene97401	NCT05827016	Map
PA	Fox Chase Cancer Center - Jeanes Campus	Philadelphia19111-2433	NCT05827016	Map
PA	Thomas Jefferson University Hospital	Philadelphia19107	NCT05827016	Map
PA	University of Pittsburgh - Hillman Cancer Center	Pittsburgh15232	NCT05827016	Map
TN	West Cancer Center	Germantown38138-1762	NCT05827016	Map
TN	Tennessee Oncology	Nashville37203-1625	NCT05827016	Map
TN	Tennessee Oncology	Nashville37203	NCT06121843	Map
TN	Vanderbilt University/Ingram Cancer Center	Nashville37232	NCT06232044	Map
TX	Texas Oncology - Baylor Charles A. Sammons Cancer Center	Dallas75246	NCT05827016	Map
TX	UT Southwestern-Harold C. Simmons Cancer Center	Dallas75390-0001	NCT05827016	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030-4000	NCT05827016	Map
TX	University of Texas MD Anderson Cancer Center	Houston77030	NCT06121843	Map
TX	UT MD Anderson Cancer Center	Houston77030	NCT05169515	Map
UT	Huntsman Cancer Institute/University of Utah	Salt Lake City84112	NCT06232044	Map
VA	VCU Massey Comprehensive Cancer Center	Richmond23298	NCT06465316	Map
WA	Fred Hutchinson Cancer Center	Seattle98109	NCT06215118	Map
WA	Swedish Medical Center - Seattle /ID# 268052	Seattle98104	NCT06896916	Map
WA	University of Washington	Seattle98195	NCT06215118	Map
WI	Saint Vincent Hospital Cancer Center at Saint Mary's	Green Bay54303	NCT06232044	Map
WI	Saint Vincent Hospital Cancer Center Green Bay	Green Bay54301	NCT06232044	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06215118	Map
WI	Medical College of Wisconsin	Milwaukee53226	NCT06232044	Map
WI	ProHealth D N Greenwald Center	Mukwonago53149	NCT06232044	Map
WI	ProHealth Oconomowoc Memorial Hospital	Oconomowoc53066	NCT06232044	Map
WI	Saint Vincent Hospital Cancer Center at Sheboygan	Sheboygan53081	NCT06232044	Map
WI	Sheboygan Physicians Group	Sheboygan53081	NCT06232044	Map
WI	Saint Vincent Hospital Cancer Center at Sturgeon Bay	Sturgeon Bay54235-1495	NCT06232044	Map
WI	ProHealth Waukesha Memorial Hospital	Waukesha53188	NCT06232044	Map
WI	UW Cancer Center at ProHealth Care	Waukesha53188	NCT06232044	Map

Iberdomide clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	suspended	not yet recruiting	available	Total
Early P1		1						1
P1	6		2	1				9
P1/P2	5	2				1		8
P2	5	6			1			12
P3	2	1				1		4
N/A							1	1

Recruiting Iberdomide clinical trials (20)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06896916	IVStudy of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma	P1	Multiple Myeloma	135	Aug 2025
NCT05827016	A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma	P3	Multiple Myeloma	1,216	Jun 2023
NCT06518551	Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM	P1/P2	Myeloma	49	Nov 2024
NCT06762769	MODIFYIsatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma	P2	Smouldering Myeloma	63	Jun 2025
NCT06785415	Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma	P1/P2	Recurrent Multiple Myeloma	37	Mar 2025
NCT05272826	BOREALISStudy of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients	P2	Multiple Myeloma	75	Dec 2024
NCT05896228	Iber-KDdIberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma	P2	Refractory Multiple Myeloma	30	Feb 2024
NCT06232044	Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	P1/P2	Recurrent Multiple Myeloma	88	Apr 2025
NCT07437963	Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse	P1/P2	Recurrent Ganglioneuroblastoma	76	Jul 2026
NCT05169515	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	P1	Non-Hodgkin Lymphoma	121	Oct 2022
NCT04776395	Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma	P2	Smoldering Plasma Cell Myeloma	68	Jul 2021
NCT06348108	Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma	P1	Multiple Myeloma	32	Jul 2025
NCT06216158	Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma	P3	Multiple Myeloma	411	Apr 2024
NCT05558319	GEM21menos65NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide	P3	Newly Diagnosed Multiple Myeloma	480	Oct 2022
NCT06121843	BMS-986393A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	P1	Multiple Myeloma	147	Feb 2024
NCT05583617	PLYCOMA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma	P1/P2	Multiple Myeloma	200	Nov 2023
NCT06215118	PF-06863135A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)	P1	Multiple Myeloma	87	Feb 2024
NCT06465316	TECVAYLITesting Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma	P1	Recurrent Multiple Myeloma	26	Dec 2024
NCT06107738	IBEXIberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma	P2	Multiple Myeloma	60	Dec 2023
NCT05199311	CC-220Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma	P1/P2	Multiple Myeloma	66	May 2022

Iberdomide clinical trials by indication

Multiple Myeloma (20)

NCT	Acronym	Phase	Status	Title
NCT06896916	IV	P1	recruiting	Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05827016	—	P3	recruiting	A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT04975997	EXCALIBER-RRMM	P3	active not recruiting	Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05272826	BOREALIS	P2	recruiting	Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
NCT05177536	—	P2	active not recruiting	Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
NCT05527340	—	P2	active not recruiting	Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.
NCT06348108	—	P1	recruiting	Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
NCT06216158	—	P3	recruiting	Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma
+ 12 more, see All trials below.

Recurrent Multiple Myeloma (3)

NCT	Acronym	Phase	Status	Title
NCT06785415	—	P1/P2	recruiting	Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
NCT06232044	—	P1/P2	recruiting	Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
NCT06465316	TECVAYLI	P1	recruiting	Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Recurrent Ganglioneuroblastoma (1)

NCT	Acronym	Phase	Status	Title
NCT07437963	—	P1/P2	not yet recruiting	Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

Smouldering Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT06762769	MODIFY	P2	recruiting	Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma

Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT06518551	—	P1/P2	recruiting	Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Refractory Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05896228	Iber-KDd	P2	recruiting	Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Healthy Volunteers (1)

NCT	Acronym	Phase	Status	Title
NCT05899738	CC-220	P1	completed	A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

Newly Diagnosed Multiple Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05558319	GEM21menos65	P3	not yet recruiting	NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

Non-Hodgkin Lymphoma (1)

NCT	Acronym	Phase	Status	Title
NCT05169515	—	P1	recruiting	A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Plasma Cell Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT05392946	—	P1/P2	active not recruiting	Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Multiple Myeloma at First Relapse (1)

NCT	Acronym	Phase	Status	Title
NCT04998786	I2D IFM2021_03	P2	active not recruiting	A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."

Renal Insufficiency (1)

NCT	Acronym	Phase	Status	Title
NCT04933747	CC-220	P1	completed	Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function

Smoldering Plasma Cell Myeloma (1)

NCT	Acronym	Phase	Status	Title
NCT04776395	—	P2	recruiting	Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma

Other (1)

NCT	Acronym	Phase	Status	Title
NCT07434960	—	N/A	available	Expanded Access for Iberdomide

Iberdomide pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
EXCALIBER-RRMM	NCT04975997	P3	active not recruiting	Multiple Myeloma	939	—
GEM21menos65	NCT05558319	P3	not yet recruiting	Newly Diagnosed Multiple Myeloma	480	—
MODIFY	NCT06762769	P2	recruiting	Smouldering Myeloma	63	—
BOREALIS	NCT05272826	P2	recruiting	Multiple Myeloma	75	—
Iber-KDd	NCT05896228	P2	recruiting	Refractory Multiple Myeloma	30	—
I2D IFM2021_03	NCT04998786	P2	active not recruiting	Multiple Myeloma at First Relapse	75	—
ICON	NCT04392037	P2	active not recruiting	Multiple Myeloma	60	—
AHCT	NCT05354557	P2	active not recruiting	Multiple Myeloma	16	—
IBEX	NCT06107738	P2	recruiting	Multiple Myeloma	60	—

Terminated and withdrawn Iberdomide trials (2)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT06179888suspendedIberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT05289492terminatedStudy of Novel Regimens in Relapsed or Refractory Multiple Myeloma

All Iberdomide trials (35)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06896916	IV	Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma	P1	recruiting	135	AbbVie	Aug 2025
NCT05827016		A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma	P3	recruiting	1,216	Bristol-Myers Squibb	Jun 2023
NCT06518551		Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM	P1/P2	recruiting	49	Omar Nadeem, MD	Nov 2024
NCT06762769	MODIFY	Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma	P2	recruiting	63	University College, London	Jun 2025
NCT04975997	EXCALIBER-RRMM	Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)	P3	active not recruiting	939	Celgene	Jun 2022
NCT06785415		Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma	P1/P2	recruiting	37	Mayo Clinic	Mar 2025
NCT05272826	BOREALIS	Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients	P2	recruiting	75	Canadian Myeloma Research Group	Dec 2024
NCT05896228	Iber-KDd	Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma	P2	recruiting	30	Benjamin T Diamond, MD	Feb 2024
NCT05177536		Iberdomide Maintenance Therapy in Patients With Multiple Myeloma	P2	active not recruiting	40	University of Nebraska	Jun 2022
NCT06232044		Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma	P1/P2	recruiting	88	Alliance for Clinical Trials in Oncology	Apr 2025
NCT04998786	I2D IFM2021_03	A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."	P2	active not recruiting	75	Nantes University Hospital	Dec 2021
NCT05527340		Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.	P2	active not recruiting	140	PETHEMA Foundation	Dec 2022
NCT07437963		Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse	P1/P2	not yet recruiting	76	National Cancer Institute (NCI)	Jul 2026
NCT05169515		A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma	P1	recruiting	121	Hoffmann-La Roche	Oct 2022
NCT04776395		Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma	P2	recruiting	68	Emory University	Jul 2021
NCT06348108		Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma	P1	recruiting	32	Alfred Chung, MD	Jul 2025
NCT06216158		Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma	P3	recruiting	411	University of Heidelberg Medical Center	Apr 2024
NCT05558319	GEM21menos65	NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide	P3	not yet recruiting	480	PETHEMA Foundation	Oct 2022
NCT05392946		Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study	P1/P2	active not recruiting	49	Mayo Clinic	Aug 2022
NCT05434689	COMMANDER	COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide	P1/P2	active not recruiting	80	University of Alabama at Birmingham	Jan 2023
NCT06121843	BMS-986393	A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma	P1	recruiting	147	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	Feb 2024
NCT05583617	PLYCOM	A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma	P1/P2	recruiting	200	Hoffmann-La Roche	Nov 2023
NCT06215118	PF-06863135	A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)	P1	recruiting	87	Pfizer	Feb 2024
NCT04564703		Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients	P2	active not recruiting	160	Stichting European Myeloma Network	Feb 2021
NCT04392037	ICON	Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone	P2	active not recruiting	60	Amsterdam UMC, location VUmc	Feb 2021
NCT06179888		Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma	P2	suspended	78	National Cancer Institute (NCI)	Aug 2024
NCT05354557	AHCT	Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)	P2	active not recruiting	16	Memorial Sloan Kettering Cancer Center	Apr 2022
NCT06465316	TECVAYLI	Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma	P1	recruiting	26	National Cancer Institute (NCI)	Dec 2024
NCT06107738	IBEX	Iberdomide and Daratumumab As Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma	P2	recruiting	60	Barbara Ann Karmanos Cancer Institute	Dec 2023
NCT05560399	CC-220	A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma	Early P1	active not recruiting	7	Icahn School of Medicine at Mount Sinai	Feb 2023
NCT05199311	CC-220	Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma	P1/P2	recruiting	66	Hackensack Meridian Health	May 2022
NCT07434960		Expanded Access for Iberdomide	—	available	0	Bristol-Myers Squibb	—
NCT05289492		Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma	P1	terminated	16	iTeos Therapeutics	May 2022
NCT05899738	CC-220	A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants	P1	completed	32	Bristol-Myers Squibb	May 2023
NCT04933747	CC-220	Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function	P1	completed	26	Celgene	Aug 2021

Iberdomide clinical trials: frequently asked questions

How many Iberdomide clinical trials are there?: 35 Iberdomide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 18 are actively recruiting participants. 2 are marked completed.
Are Iberdomide clinical trials recruiting in 2026?: Yes — 18 Iberdomide trials are actively recruiting in 2026, with 165 U.S. sites across 33 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Iberdomide being studied for?: Iberdomide is being studied for Multiple Myeloma, Refractory Multiple Myeloma, Recurrent Multiple Myeloma, Relapsed Multiple Myeloma, Non-Hodgkin Lymphoma and 12 more. The trials are grouped by indication on this page.
What phase is Iberdomide in?: Iberdomide clinical trials span 4 Phase 3, 12 Phase 2, 9 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Iberdomide clinical trials?: The lead sponsor across the most Iberdomide trials is Bristol-Myers Squibb, with 26 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Iberdomideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 12, 2026.

Related pages on Hipa.ai:

Iberdomide overview